HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $8 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Bolt Biotherapeutics (NASDAQ:BOLT) and maintains an $8 price target.
June 05, 2023 | 10:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Bolt Biotherapeutics and maintains an $8 price target.
The reiterated Buy rating and maintained $8 price target by HC Wainwright & Co. analyst Edward White indicates a positive outlook for Bolt Biotherapeutics. This news is likely to have a positive short-term impact on BOLT's stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100